The Magnet Committee, under the auspices of the Office of the Chief Scientist, has approved a grant of NIS 39.2 million for the support of 13 projects under the Nofar program, dedicated to the research and development in biotechnology and nanotechnology.
The Nofar program aims to advance academic research to where it is ready for a cooperative venture with a commercial or industry partner. Industry players involved in the approved projects include Teva Pharmaceuticals, Johnson & Johnson and Intel.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>